Belgian Grower Tomerel Increases Light Levels, Decreases Energy Costs Through Fluence LED Retrofit
12.5.2022 15:00:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its partnership with Tomerel, a tomato grower located in Antwerp, Belgium. Together, the companies retrofitted half of Tomerel’s glasshouse from high-pressure sodium (HPS) fixtures to LEDs, resulting in a 40% increase in light levels while decreasing energy input by 5%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005116/en/
Tomerel is a multi-generational family farm led by CEO and co-owner Jelle de Ryck—son of founders Els and Eric. Tomerel specializes in glasshouse-grown tomatoes, with a particular focus on cherry tomatoes on the vine. Like many growers in the region, Jelle de Ryck scaled his family’s facility using supplemental HPS fixtures. However, when Jelle sought to maximize the glasshouse’s light output and energy consumption, he turned to Fluence’s advanced LED technology.
“When we set out to identify a partner to assist with our lighting retrofit, we weren’t just looking for lights—we wanted a team that could strategize with us from installation through harvesting. Fluence provided that service and more,” said Jelle.
After installing Fluence’s VYPR 3p top light solution, what were once critical limitations to the farm’s lighting strategy became opportunities to boost yields and reduce energy costs. Traditional HPS fixtures produce excess heat and feature inflexible spectral options. Fluence LEDs, however, run cooler and use a more efficient spectrum. With exploding energy prices in the region, the lightened load on the glasshouse’s HVAC system, in combination with the LEDs’ overall more efficient energy usage, enabled Tomerel to cut its electricity usage while increasing light levels.
“Fluence’s technology drove success for us in multiple ways. The electricity efficiencies enabled us to sell 25% more energy back to the grid and also reduced our gas consumption by 5%. The plants are also thriving under LEDs. We’re seeing improved quality and production throughout the winter months, increases in stem density and improved translocation of sugars throughout the night,” Jelle added.
In close coordination with Fluence’s technical team, Tomerel implemented a PhysioSpec™ DUAL R9B spectral strategy to accommodate plant efficacy. This strategy enabled Tomerel to decrease energy input by 5% even while increasing the amount of light by 40%, ensuring stronger cultivation conditions for Tomerel’s tomato crop. As a result, Tomerel also increased its yield by more than 5% despite the facility receiving 5% less natural light over the winter season. Tomerel also saw an increase in overall fruit weight following the retrofit.
“It is fascinating to see growers like Tomerel make innovative, smart cultivation decisions regarding energy usage,” said Timo Bongartz, general manager for Europe, the Middle East and Africa for Fluence. “The Tomerel team is saving energy wherever possible and also optimizing their facility in such a way to enable them to sell energy back to the grid. And all that without sacrificing plant quality. Fluence is delighted to support Tomerel in running a future-proof glasshouse.”
With Fluence’s technology, the Tomerel team sold 25% more of the glasshouse’s electricity produced by co-generation back to the grid during peak energy prices and saved 5% of its total gas consumption.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005116/en/
Contact information
For Fluence
Emma Chase
pr@fluencebioengineering.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
